Trellis Bioscience, Inc.
Trellis Bioscience is a biotechnology company leveraging its proprietary CellSpot™ technology to discover and develop native human monoclonal antibodies for the treatment and prevention of infectious diseases and cancer. The company focuses on targeting bacterial, viral, and cancer indications with a portfolio of therapeutics that have demonstrated efficacy in model systems. Trellis aims to harness the human immune system's natural antibody responses to create safer and more effective treatments, with a strong emphasis on disrupting biofilms, combating antimicrobial resistance, and targeting tumor-associated antigens.
Industries
Nr. of Employees
medium (51-250)
Trellis Bioscience, Inc.
San Francisco, California, United States, North America
Products
TRL1068 (calpurbatug)
Native human monoclonal antibody that binds a conserved biofilm scaffolding protein family to disrupt bacterial biofilm and restore antibiotic susceptibility.
TRL345
High-affinity native human monoclonal antibody against a conserved site on cytomegalovirus (glycoprotein B) with demonstrated neutralization across clinical isolates and activity in placental/ex vivo models.
CF404 (pan-influenza antibody cocktail)
Cocktail of three monoclonal antibodies targeting conserved regions across influenza A and B strains, developed for broad-spectrum post-infection efficacy.
TRL3D3
Native human monoclonal antibody targeting a conserved region of the RSV G glycoprotein with direct antiviral activity and modulation of immune effects associated with the G protein.
TRL10001 (anti-ALK)
High-affinity human monoclonal antibody recognizing the extracellular domain of ALK that internalizes rapidly in ALK-expressing tumor cells, assessed for antibody–drug conjugate opportunities.
TRL1068 (calpurbatug)
Native human monoclonal antibody that binds a conserved biofilm scaffolding protein family to disrupt bacterial biofilm and restore antibiotic susceptibility.
TRL345
High-affinity native human monoclonal antibody against a conserved site on cytomegalovirus (glycoprotein B) with demonstrated neutralization across clinical isolates and activity in placental/ex vivo models.
CF404 (pan-influenza antibody cocktail)
Cocktail of three monoclonal antibodies targeting conserved regions across influenza A and B strains, developed for broad-spectrum post-infection efficacy.
TRL3D3
Native human monoclonal antibody targeting a conserved region of the RSV G glycoprotein with direct antiviral activity and modulation of immune effects associated with the G protein.
TRL10001 (anti-ALK)
High-affinity human monoclonal antibody recognizing the extracellular domain of ALK that internalizes rapidly in ALK-expressing tumor cells, assessed for antibody–drug conjugate opportunities.
Expertise Areas
- Monoclonal antibody discovery from human memory B-cells
- Multiplexed antigen screening and epitope mapping
- Preclinical infectious disease models and biofilm therapeutics
- Clinical trial design and early-phase execution
Key Technologies
- Single-cell multiplexed B-cell screening
- Computerized high-throughput microscopy
- Multiplexed antigen binding assays
- X-ray crystallography